Podcasts about Fujifilm

Episode 470 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - 20% OFF Nanlite PavoTube II XR and kits at NanliteUS.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Adobe announces some potentially useful new features. (#) Sigma's new 17-40mm f/1.8 DC Art. (#) Profoto's new B20 and B30 monolights. (#) Peak Design's latest tripod Kickstarter. (#) Godox's V480C TTL flash. (#) Leica's first filmstock to celebrate 100 years of this. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

"In each place I have travelled, I have used my camera as an extension of my memory." -- Teju Cole "In photography and in life, always look for the light, if you don't see it, bring it."  John Waire   In this episode, Antonio records from Brooklyn for the last time before his big move to Nebraska. It's a reflective and unscripted conversation, touching on the chaos of packing, the emotional weight of leaving, and a perfectly timed rainbow that showed up outside his window. He and Ward talk about the kind of weather that begs to be photographed and how certain visual moments trigger memories of past images—like Ernst Haas' dramatic skies. Antonio also shares how instant photography is playing a bigger role in his life lately, especially with the Polaroid and Instax cameras he's bringing on the road trip west. Ward recounts how he unexpectedly became the unofficial wedding photographer at a recent event, armed only with a Fuji XS20 and a 23mm lens. What was supposed to be a casual favor turned into a full-on assignment, and he reflects on how his street photography instincts kicked in to help him adapt. They also talk about the overlap between documentary and wedding photography, the influence of photographers like Kevin Mullins and Mel DiGiacomo, and how shooting in a “real life” environment brings out surprising results. There's also a bit of Fujifilm gear talk, some thoughts on photo printing with Polaroid's phone-based printer, and the occasional side trip into DIY diffuser hacks using deli containers.    Subscribe to our Substack Newsletter Help out the show by buying us a coffee! Support the show by purchasing Antonio's Zines. Send us a voice message, comment or question.   Show Links:   Antonio M. Rosario's Website, Vero, Instagram, Bluesky, and Facebook page Ward Rosin's Website, Vero, Bluesky, Instagram and Facebook page. Ornis Photo Website  The Unusual Collective Street Shots Facebook Page Street Shots Instagram     Subscribe to us on: Apple Podcasts Google Podcasts Spotify Amazon Music iHeart Radio

Episode 469 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - 20% OFF Nanlite PavoTube II XR and kits at NanliteUS.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: The X-E5 and XF23mm f/2.8 R WR. (#) Laowa's 8-15mm fisheye wide-zoom. (#) Nikon's latest Z8 firmware adds useful features. (#) ON1 turns 20. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Photografix-News ist EUER News-Podcast rund um alle Themen der Digitalen Fotografie!

This week, we're joined by Matt Workman—filmmaker, developer, and creator of Cine Tracer—for a candid look at the shifting landscape of cinematography. We explore how filmmakers can better communicate, justify resources, and protect their creative choices in a rapidly evolving industry, and why futureproofing your skillset now means knowing both a light meter and a game engine. From the emergence of virtual production to the democratization of 3D previsualization, Workman unpacks how technology like Unreal Engine, once reserved for high-budget productions, is becoming a daily tool for working DPs.Matt Workman's Instagram | YouTubePeter Pascucci's Instagram | WebsiteLauren Guiteras's Instagram | WebsiteThis episode is sponsored by Fujifilm, Sandisk and TCP Insurance.

Want to take your photography and your business to the next level? It's not always about buying the latest gear - sometimes, it's the little-known tricks and techniques that make the biggest difference. In this episode, we're revealing some photography secrets that can instantly improve your work and how you run your business.  Whether you're a seasoned photographer or just starting out, there's something in this episode that will change the way you shoot. Tune in and start capturing your best work yet! Episode Promos This episode contains promos for: Elementor Wordpress Website Builder - https://nerdyphotographer.com/recommends/elementor Aftershoot AI Culling - https://aftershoot.com/explore/?ref=nerdyphoto10 Siteground Website Hosting - https://www.siteground.com/go/nerdy Support The Nerdy Photographer Want to help The Nerdy Photographer Podcast? Here are a few simple (and mostly free) ways you can do that: Subscribe to the podcast! Tell your friends about the podcast Sign up for the newsletter - https://nerdyphotographer.com/newsletter Buy a print from the print shop - https://caseyfatchettphotography.pic-time.com/art Follow on Instagram - https://instagram.com/thenerdyphoto Follow on Threads - https://threads.net/@thenerdyphoto Follow in Tiktok - https://tiktok.com/@thenerdyphoto Subscribe to our YouTube Channel - https://www.youtube.com/@CaseyFatchett Get some Nerdy Photographer merchandise - https://www.teepublic.com/stores/nerdy-photographer If you're feeling extra generous, check out our support page - https://nerdyphotographer.com/support-nerdy-photographer/ About My Guest Fred Agho is a Houston-based commercial and portrait photographer who started his journey capturing his collegiate football teammates. His passion for photography has grown into a talent for creating striking portraits that feel authentic and deeply connected. Drawing from his own life experiences, Fred brings a unique perspective to his work, capturing people in a way that feels natural and true to who they are. His ability to connect with his subjects and tell their stories visually has made him a sought-after name in the industry. With an impressive client list that includes FUJIFILM, Publix, SNKR App, Amazon, and Premium Goods, Fred has built a reputation for delivering high-quality, impactful imagery. Each project sharpens his skills and expands his creative vision, resulting in a portfolio filled with compelling and memorable images. You can see Fred's work at his website - https://www.fujifred.com or on Instagram https://instagram.com/@FREDAGHO About The Podcast The Nerdy Photographer Podcast is written and produced by Casey Fatchett. Casey is a professional photographer in the New York City / Northern New Jersey with more than 20 years of experience. He just wants to help people and make them laugh. You can view Casey's wedding work at https://fatchett.com or his non-wedding work at https://caseyfatchettphotography.com    If you have any questions or comments about this episode or any other episodes, OR if you would like to ask a photography related question or have ideas for a topic for a future episode, please reach out to us at https://nerdyphotographer.com/contact  

In this Cine Gear 2025 wrap-up episode of CineD Focus Check, Johnnie is joined by acclaimed cinematographer Markus Förderer, ASC (Red Notice, I Origins, Stowaway) for a rich and thoughtful conversation. Set against the cinematic backdrop of the Universal Studios lot, the two dive deep into the current state of lens technology, digital cinematography, and the importance of preserving the emotional core of storytelling amidst rapid technological change, and the state of the filmmaking industry in general. This Cine Gear 2025 wrap-up episode is sponsored by FUJIFILM. Check out this week's educational One-Minute Tip from them at (08:40)! Markus joined us once before over a year ago in a prior episode of the Focus Check podcast, talking about his project CineFlares after it launched, and his work on Constellation. Check it out here if you missed that episode. From discussing metadata integration in modern lenses and the rise of affordable anamorphic glass, to reflecting on the potential and limitations of AI-generated visuals, this episode offers a grounded and inspiring perspective from one of Hollywood's most thoughtful DPs. Markus also shares insights on his lens test platform CineFlares, custom LUT workflows, and how he chooses optics based on narrative needs, not specs. If you're passionate about the intersection of story, gear, and artistry — this one's for you. Chapters & Show Notes: (00:00) - Intro and Cine Gear impressions Johnnie and Markus open the episode from Cine Gear LA 2025 at Universal Studios and share first impressions of the show. (01:04) - Markus Förderer on his career and latest work From Germany to Hollywood — Markus talks about September 5 (available on Apple TV), Red Notice, and Independence Day: Resurgence. (02:08) - CineFlares: Lens testing reimagined Markus introduces CineFlares.com, a motion-control-based lens test platform with over 100 lens sets and 1,500+ clips. (03:56) - What impressed Markus at Cine Gear He discusses new smart lens tech, metadata tracking, and RED/Nikon's collaboration with Preston. (04:40) - Lens metadata and autofocus on large productions Why autofocus still can't replace a good focus puller — and how hybrid systems are evolving. (07:40) - Small AF rigs for solo shoots Markus shares a jungle shoot story using PDMovie's compact autofocus motor system. https://www.cined.com/pdmovie-live-air-2s-worlds-smallest-wireless-follow-focus-handwheel/ (09:40) - Favorite new lenses at Cine Gear Iron Glass, Zero Optik chip mounts for metadata, and the new Xelmus Apollo “Aura” lenses. (11:28) - Sigma's AIZU full-frame High-Speed Prime line A look at Sigma's new AIZU 1.3 T-stop cine primes and their unique three-dimensional character. https://www.cined.com/sigma-aizu-cinema-prime-lenses-a-talk-with-kazuto-yamaki-san/ (14:10) - What makes a lens cinematic? Markus discusses personality, bokeh, barrel distortion, and why clean ≠ compelling. (18:24) - Flare behavior and subconscious texture How internal lens reflections subtly shape the emotional feel of an image. (19:22) - Affordable anamorphics: SIRUI IronStar A hands-on look at SIRUI's 1.5x squeeze lens series, priced around $1,200. https://www.cined.com/sirui-ironstar-1-5x-t1-9-anamorphic-full-frame-cine-lens-announced/ (23:00) - Cameras that stood out Markus reacts to FUJIFILM's upcoming GFX ETERNA cinema camera and its internal film emulation science. https://www.cined.com/fujifilm-gfx-eterna-2025-release-confirmed-new-technical-details-explained/ (25:09) - FX2, rolling shutter, and global shutter tech The pros and cons of older sensors, rolling shutter artifacts, and RED Komodo X's global shutter advantage. (30:00) - Industry mood check: post-strike recovery Markus sees improving energy in the industry, with more global shoots and cautious optimism. (31:58) - Long takes and storytelling rhythm Thoughts on Apple's The Studio, one-take shots, and why editing still matters emotionally. (34:30) - AI image generation and its limitations Markus argues that real, human-captured moments can't be replaced by AI dream-logic imagery. (37:02) - Final thoughts and sign-off A warm Cine Gear 2025 wrap-up with hopes to reconnect at the same show next year — and a reminder to leave your comments below. Thanks for watching/listening — if you enjoyed this conversation, don't forget to like and subscribe on YouTube and your favorite podcasting platform, and let us know in the comments which topic resonated most with you. See you next time on CineD Focus Check!

With a PetaPixel Membership, not only can you support original PetaPixel reporting and in-depth reviews, but you can also remove ads from the website and gain access to some seriously great perks, too. Members get $15 off the Moment Store, 25% off the PetaPixel Merch Store, and now can download full-resolution RAW files and JPEGs from the latest cameras and lenses. It costs just $3 per month or $30 per year. Join today.Running a camera store is hard enough as it is, but add the complexity of the 2025 economic environment, and The Camera Store's founder Peter Jeune has his work cut out for him. This week on the PetaPixel Podcast, he joins the team to give an update on navigating the fluctuating pricing and product popularity so far in 2025.Check out PetaPixel Merch: store.petapixel.com/ We use Riverside to record The PetaPixel Podcast in our online recording studio.We hope you enjoy the podcast and we look forward to hearing what you think. If you like what you hear, please support us by subscribing, liking, commenting, and reviewing! Every week, the trio go over comments on YouTube and here on PetaPixel, but if you'd like to send a message for them to hear, you can do so through SpeakPipe.In This Episode:00:00 - Intro12:49 - Firstly, no the Kyu review wasn't sponsored content15:13 - Fujifilm moved manufacturing for four X series camera to Japan just for the US market18:41 - We got a ton of new info about the GFX Eterna23:20 - iPadOS is finally getting the update Chris desperately wants27:55 - The SmallRig x Potato Jet tripod is now available in a more compact version31:36 - 31:36 - 7Artisans Cine Primes promise pro quality for $80038:25 - Omnar Lenses made the 5cm f/2 MC FLB lens42:04 - The Camera Store's Peter Jeune talks 2025 pricing and camera popularity1:19:31 - What have you been up to?1:26:16 - Tech support1:36:41 - Feel good story of the week

Photografix-News ist EUER News-Podcast rund um alle Themen der Digitalen Fotografie!

Once again I Dream of Cameras spans the globe, with Jeff in Prague and Gabe in Los Angeles, and not even a nine-hour time difference can slow us down! In fact, one might say we are utterly devoid of camera viscosity, or “camerosity” for short. In this supersized episode…Jeff unknowingly chatted up Danny Clinch about his Leica Q2 at the Trombone Shorty Soho Session, and the acclaimed photographer was faintly dismissivefor the next two months Jeff's in Prague, where the camera shops (FotoŠkoda, Jan Pazdera) are far too alluringhe's been eyeing a lovely Zeiss Tenax II, a flawed Olympus 35SPn, and a beautifully brassed black Canonflex RMbefore departure, Jeff did the unthinkable: snagged a bargain-basement half-frame Alpa 10s on the ‘Bay - it's half a Swiss cookie and the realization of a lifelong dream!talking Leicas with Dave Tada, Gabe realized he needs a 35mm lens for his Leica III - he already has the 50mm Serenar, so any suggestions?Gabe went to the Fujifilm event for their bizarre new half-a-cookie digital - what did he learn about the elusive x100vi?Gabe has gone half-cookie INSANE with his Olympus Pen FT, so now our friend Sissi Lu has enticed him to give the Pentax One Seven one more try - what will he grab next, the chunky plastic Pentax or the mighty meterless Olympus Pen FV?he's got a portrait shoot coming up, and plans to use the Kiev 60, the Leica III and the Mamiya RZ67as for replenishing his collection, he's up to 27 of a planned 30 cameras Jeff was shooting around Prague when Sudden Fujifilm Battery Death struck again! Fuji's battery displays in both the XPan and GA645 are pure fictionGabe's also been rebuilding his book collection with Duane Michals Portraits and volumes by Sarah Moon and Clifford Coffinlet us now praise John Wade's Retro Cameras, which is what Ralph Bellamy's book should have beenonce again we make it halfway down the depths of our Prodigious Mailbag™Gabe unleashes a raft of thank-yousand adds a final postscript: nature is healing and he's back in the bag business, welcoming a new Nomatic Luma McKinnon

In this episode, we were fortunate to be connected through Blackmagic Design with Victor from TARGO, a Paris-based production company that has been pushing the boundaries of immersive storytelling from the very beginning. Their latest project, “D-Day: The Camera Soldier”, is a groundbreaking documentary created specifically for the Apple Vision Pro. It blends historical footage with interactive and immersive elements, offering a completely new way to experience this pivotal moment in history. Nino and Victor discuss the unique technical challenges involved in producing content for the Vision Pro, and explore why the effort is worthwhile despite the complexities. They also share their vision for how immersive production could become more accessible in the near future, especially with tools like the upcoming Blackmagic URSA Cine Immersive — which we also reported about. In case you own an Apple Vision Pro you can find the Documentary here: https://apps.apple.com/at/app/d-day-the-camera-soldier/id6737838494?l=en-GB Here you can find more infos about TARGO and their Projects: https://www.targostories.com/dday-the-camera-soldier Sponsor: This episode is sponsored by FUJIFILM. Check it out at 26:08 Chapters & Articles Mentioned in This Episode: (00:00) – Introduction: Exploring Immersive Storytelling (01:29) – Background on TARGO and Their Vision (05:37) – Conceptualizing “D-Day: The Camera Soldier” (08:36) – Technical Challenges in Immersive Filmmaking (14:38) – Utilizing Apple Vision Pro Capabilities (18:55) – Integrating Historical Footage and Interactive Elements (21:27) – Post-Production Workflow and Tools (27:40) – Audience Reception and Feedback (31:52 ) – Future of Immersive Documentaries (39:04) – Closing Thoughts and Takeaways   We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com 

TurdOrTreasure is ThisWeekInGeek's dedicated review show covering everything from games to movies to tv to electronics and everything between.This Episode:What's New?Fujifilm Printlife Personalized NHL: https://fujifilmprintlife.ca/collections/nhlGames First Impressions Reviews -Warhammer 40,000: Speed Freeks - https://store.steampowered.com/app/2078450/Warhammer_40000_Speed_Freeks/Home - https://store.steampowered.com/app/2575940/Home/Starlight Legacy - https://www.xbox.com/en-us/games/store/starlight-legacy/9P37KTW0D2TNEnGenius ECW516L Wifi 7 AP (Networking Tech Review) - https://www.engeniustech.com/engenius-products/cloud-managed-2x3x3-lite-indoor-tri-band-wifi-7-access-point/The Outlaw Josie Wales (Warner 4K Review) - https://www.blu-ray.com/movies/The-Outlaw-Josey-Wales-4K-Blu-ray/382392/Pale Rider (Warner 4K Review) - https://www.blu-ray.com/movies/Pale-Rider-4K-Blu-ray/382393/Pipistrello And The Cursed Yoyo (PM Studios Inc PC Steam Review) - https://store.steampowered.com/app/2870350/Pipistrello_and_the_Cursed_Yoyo/Your Geekmaster:Alex "The Producer" - https://bsky.app/profile/dethphasetwig.bsky.socialFeedback for the show?:Email: feedback@thisweekingeek.netTwitter: https://twitter.com/thisweekingeekBluesky: https://bsky.app/profile/thisweekingeek.bsky.socialYouTube: https://www.youtube.com/channel/UCc1BfUrFWqEYha8IYiluMyAiTunes: https://podcasts.apple.com/us/podcast/this-week-in-geek/id215643675Spotify: spotify:show:0BHP4gkzubuCsJBhU3oNWXCastbox: https://castbox.fm/channel/id2162049Website: https://www.thisweekingeek.netJune 3, 2025

Dalton Johnson (@storiesbydalton) is a photographer, adventurer, and journalist who has collaborated with renowned brands such as Patagonia, Big Agnes, and Rivian.In this episode, Dalton shares his own experiences in an effort to help photographers understand how they can leverage free work as a tool for growth, the importance of persistence in marketing their craft, and the cyclical process of building a thriving creative career. He breaks down actionable strategies for repeatedly turning passion projects into paid opportunities and shares insights into crafting effective pitches, balancing art with personal fulfillment, and creating work that connects deeply with both clients and audiences.Expect to Learn:Why free work is a powerful tool to build a portfolio and create ROIThe never ending cyclical process of having an idea, creating a body of work, and marketing itWhy engaging with multiple companies daily, will lead to meaningful client relationshipsPractical methods to market creative projectsHelpful tips on creating effective pitchesDalton's links:Youtube: https://www.youtube.com/@storiesbydaltonWebsite: https://dalton-johnson.com/LinkedIn: https://www.linkedin.com/in/daltonjohnsonmedia/Sponsor:Thanks to Tamron for being our lead sponsor this episode! Explore the 18-300mm all-in-one zoom lens for Fujifilm and Sony APS-C Mirrorless cameras and soon for Nikon Z and Canon RF mounted cameras. Right now, enjoy $100 off on this lens! You can visit www.tamron-americas.com or your local Tamron authorized dealer. Our Links:Join our subreddit where you can share stories and ask questions:https://www.reddit.com/r/photographermindset/Subscribe to TPM's Youtube page and watch full length episodes: https://www.youtube.com/thephotographermindset/Make a donation via PayPal for any amount you feel is equal to the value you receive from our podcast episodes! Donations help with the fees related to hosting the show:https://paypal.me/podcasttpm?country.x=CA&locale.x=en_USThanks for listening!Go get shooting, go get editing, and stay focused.@sethmacey@mantis_photography@thephotographermindsetSupport the show

Fuji hat mit der X Half ein neues Kamera-Modell auf den Markt gebracht, das in Sachen Analog-Simulation den nächsten Schritt geht. Inspiriert davon bringt Michael mit einem schwarzen Kaffee in der Hand Ideen mit, wie im Prinzip jede Digitalkamera mit einem analogen Feeling versehen werden kann. Und stellt sich (und Euch!) die Frage: Warum das ganze überhaupt? Wir freuen uns auf Eure Kommentare, hier unter dem Post oder in der Freundeskreis-Community!

Episode 468 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Calibrite's Spring savings at Calibrite.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Fujifilm's new X half. (#) Nikon takes the top spot for the first time. (#) Sebastião Salgado passes away. (#) X Summit in Shanghai. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Finally, the long-anticipated new Sony FX2 cinema camera has arrived at the CineD headquarters for a full stress test — and that's exactly what we did. Johnnie has already spent some time with the camera, produced a short documentary, and shares insights on what worked for him and what didn't. Additionally, we cover new updates on the latest version of Google's AI video generator, Neo, along with the usual gear updates for the week. Join us to discover all the details in this "Sony FX2 podcast". Sponsor: This episode is sponsored by FUJIFILM. Check it out at 29:04 Chapters & Articles Mentioned in This Episode: (00:00) -  Intro (03:26) - Sony FX2 Review – An Entry-Level, Full-Frame, Cinema Line Camera. Is the Price Right? https://www.cined.com/sony-fx2-review-an-entry-level-full-frame-cinema-line-camera-is-the-price-right/   (30:05) - Google DeepMind Veo 3 and Flow Unveiled for AI “Filmmaking” https://www.cined.com/google-deepmind-unveils-veo-3-and-flow-for-ai-filmmaking/   (39.26) - AI Flood on Adobe Stock: Nearly Half of All Images Now AI-Generated https://www.cined.com/ai-flood-on-adobe-stock-nearly-half-of-all-images-now-ai-generated/    (42:45) - Darren Aronofsky Partners with Google DeepMind on Generative AI Short Film Initiative https://www.cined.com/darren-aronofsky-partners-with-google-deepmind-on-generative-ai-short-film-initiative/   (48:11) - B&H BILD Expo Returns to New York City in June, with CineD Talk – Free Registration Now Open https://www.cined.com/bh-bild-expo-returns-to-new-york-city-in-june-with-cined-talk-free-registration-now-open/   (50:06) - Poll: What is the Most Innovative Camera Brand? https://www.cined.com/poll-innovation-in-cameras-which-is-your-favorite-brand/   (53:19) - RØDE Wireless Micro Bluetooth iOS Update Adds Direct Pairing with iPhones https://www.cined.com/rode-wireless-micro-bluetooth-ios-update-adds-direct-pairing-with-iphones/   (55:43) - Hollyland LARK MAX 2 Officially Launched – 32-bit Float, On-board TC & Four-TX Support https://www.cined.com/hollyland-lark-max-2-officially-launched-32-bit-float-on-board-tc-four-tx-support/ (1:00:35) - Mandy Walker Makes History as ASC's First Female President https://www.cined.com/mandy-walker-makes-history-as-ascs-first-female-president/   (01:02:48) - Pro Tip: Sensor Crop Feature in CineD Lens Coverage Tool https://www.cined.com/pro-tip-sensor-crop-feature-in-lens-coverage-tool/   We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com   

Neale is trying to cheer Kev up, who is sitting in a blacked out room in beautiful Malmesbury, counting down the hours, minutes and seconds until he can escape the UK for the sunnier climes of España! On the show, the boys discuss using Pictime as an art gallery, software solutions for back-up, the foto app, fixing up a retiring camera, the best compact camera in the Fujifilm range to travel with, switching to video using an X-T4, and we also feature the Zine work of Adam Ramjean, as he photographs the Notting Hill Carnival. Email the show with your questions: click@fujicast.co.uk  Pic Time: https://www.pic-time.com/ - use FUJICAST when creating an account for discount offers to apply For links go to the showpage.

Peti evezett és futott. Godox HSS probléma a Canonnal. Egy zoom objektív opció Petinek. Hogyan építsünk fotó stúdiót olyan embernek aki nem tud fotózni?Az adás linkje:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/149⁠Támogass minket Patreonon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Csatlakozz a Tripodcast Community Facebook csoporthoz!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://tripodcast.hu/community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adást a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fujifilm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, a ⁠⁠⁠⁠⁠⁠⁠Manfrotto⁠⁠⁠⁠⁠⁠⁠ és az ⁠⁠⁠⁠Ablak Stúdió⁠⁠⁠⁠ támogatta!Kövess minket Instán:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/tripodcast_⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adásban elhangzott témák, linkek:- Manfrotto Pro Light Organiser:https://www.manfrotto.com/hu-hu/pro-light-organiser-gurulos-taska-vilagitastechnikahoz-99w-2-mb-pl-lw-99-2/- Sony Canonos videója:https://www.sonyalpharumors.com/sony-center-cyprus-posted-the-weirdest-teaser-ever-for-a-new-lens-announcement-on-june-2/- Godox RS60 LED lámpa:https://www.godox.com/product-b/RS60Bi-RS60R.htmlFujifilm X-Half:https://www.fujifilm-x.com/global/products/cameras/x-hf1/- Foldio:https://www.foldio.hu

Rachel Clark, BSC, brings a poetic realism to the screen, and in this special edition episode recorded at the Camerimage Festival, she reveals how she constructs that visual language. Joining hosts Ava Benjamin Shorr and Lauren Guiteras to reflect on the making of “Edge of Summer”, a lyrical coming-of-age film set in the haunting landscapes of Cornwall. Clark unpacks her immersive handheld approach, the challenge of lighting with only headlamps, and the deeply collaborative relationship with director Lucy Cohen. Their discussion explores the aesthetics of memory, adolescence, and the subtle power of image-making that trusts the viewer's emotional literacy.If you are enjoying the podcast, please consider supporting our efforts on Patreon.Rachel Clark's Instagram | WebsiteAva Benjamin Shorr's Instagram | WebsiteLauren Guiteras's Instagram | WebsiteThis episode is sponsored by Fujifilm, Creamsource and Sandisk, with special thanks to Kondor Blue.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

A camera that shoots half-images? Sounds unusual—but that's exactly what FUJIFILM's newly released X-Half brings to the table with its unique feature set. Join Johnnie and Nino as they dive into what makes this mysterious new camera stand out, and as always, catch up on the latest gear updates and industry news from the week. Tune in and enjoy the episode!   Sponsor: This episode is sponsored by FUJIFILM. Check it out at (24:38) Chapters & Articles Mentioned in This Episode: (00:00) -  Intro (05:00) - FUJIFILM Introduces X half  Premium Compact Digital Camera https://www.cined.com/fujifilm-x-half-camera-announced-when-analog-heritage-and-digital-capabilities-merge-together/   (16:09) - Poll: …. https://www.cined.com/poll-innovation-in-cameras-which-is-your-favorite-brand/   (17:05) - Sony Camera Sales in Early 2025 – Camera Gear and Image Sensors Support Growth Amid Wider Slowdown https://www.cined.com/sony-camera-sales-in-early-2025-camera-gear-and-image-sensors-support-growth-amid-wider-slowdown/   (25:30) - The Rolux RL-VP4D V-Mount Plate lets you ditch proprietary batteries https://www.instagram.com/reel/DJ4C6TtCr07/    (30:29) - Rolux Grand Series Professional Gold Mount Batteries Launched https://www.cined.com/rolux-grand-series-professional-gold-mount-batteries-launched/   (31:47)- ARRI Sells Claypaky, Refocuses on Core Filmmaking Technologies – Stage Lighting Brand Moves to EK Lights https://www.cined.com/arri-sells-claypaky-refocuses-on-core-filmmaking-technologies-stage-lighting-brand-moves-to-ek-lights/   (34:02) - Eddie AI Extension for DaVinci Resolve Released -Virtual Editing Assistant https://www.cined.com/eddie-ai-extension-for-davinci-resolve-released-virtual-editing-assistant/   (39:38) - Sennheiser Profile Wireless Audio Single-Channel System Released & 32-bit Float Firmware Update   https://www.cined.com/sennheiser-profile-wireless-audio-single-channel-system-released-32-bit-float-firmware-update/   (46:45) - Tilta Camera Cage for Panasonic LUMIX S1RII / S1II / S1IIE https://www.cined.com/tilta-camera-cage-for-panasonic-lumix-s1rii-s1ii-s1iie/   (49:41) - Different Types of Tracking Shots and What Emotions They Evoke https://www.cined.com/different-types-of-tracking-shots-and-what-emotions-they-evoke/   (50:50) - Laowa 15mm f/4.5 0.5X Macro Lens for Full-Frame Released https://www.cined.com/laowa-15mm-f-4-5-0-5x-macro-lens-for-full-frame-released/   (53:12) - Panasonic Offers 5-Year Extended Warranty on LUMIX S Cameras and Lenses in Europe https://www.cined.com/panasonic-offers-5-year-extended-warranty-on-lumix-s-cameras-and-lenses-in-europe/   (55:36) - Leica SL3 and SL3-S Firmware Update v3.1.1 Released – Adds New Video Formats for C4K and C6K https://www.cined.com/leica-sl3-and-sl3-s-firmware-update-v3-1-1-released-adds-new-video-formats-for-c4k-and-c6k/   (01:01:20) - OCTOPUS RAW Studio Enhances Raw Video Workflow in Adobe Premiere https://www.cined.com/octopus-raw-studio-enhances-raw-video-workflow-in-adobe-premiere/   (01:05:35) - Inside the Super Bowl Halftime Show – A Steadicam Operator's Perspective with Sean Flannery https://www.cined.com/inside-the-super-bowl-halftime-show-a-steadicam-operators-perspective-with-sean-flannery/   (01:08:16) - NANLITE Bowens Mount Projection Attachment 25°–45° Introduced https://www.cined.com/nanlite-bowens-mount-projection-attachment-25-45-introduced/   (01:09:55) - DaVinci Resolve 20 Beta 4 Adds Keyframe and Remote Monitoring Upgrades https://www.cined.com/davinci-resolve-20-beta-4-adds-keyframe-and-remote-monitoring-upgrades/   We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com 

Episode 467 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Calibrite's Spring savings at Calibrite.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Zenfolio promises to do better. (#) (#) Tamron's plan through 2026. (#) CaptureOne rebrands and adds some features. (#) TTArtisan's 35mm f/1.4. (#) Nikon discontinues the D6. (#) Nik Collection 8 is out. (#) ACDSee's Photoshop alternative. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

  "Photography is truth. The cinema is truth 24 times per second." -- Jean-Luc Godard   "What use is having a great depth of field, if there is not an adequate depth of feeling?" -- W. Eugene Smith   In this episode, Antonio and Ward catch up amid packing tape and camping plans. Antonio talks through the experience of unearthing old cameras—including a pair of Olympus XAs he didn't even realize he owned—while preparing for his move. The conversation wanders through gear talk, fond memories of a long-lost Forscher Polaroid back, and a reflective look at how certain tools and artifacts carry pieces of photographic history. Meanwhile, Ward shares a bit about an upcoming camping trip and a brief hands-on with Fujifilm's new GFX camera, which prompts a chat about who these high-megapixel cameras are really for.   Things shift toward the visual language of photography when Antonio brings up the use of shallow depth of field in shows like The Handmaid's Tale. That sparks a back-and-forth on the emotional and narrative power of selective focus, both in film and stills—from Sally Mann's large format portraits to W. Eugene Smith's documentary work. They round out the episode by poking at the growing trend of chasing a “cinematic look” in photography, discussing whether it's a meaningful stylistic choice or just another preset to scroll past.   Subscribe to our Substack Newsletter Help out the show by buying us a coffee! Support the show by purchasing Antonio's Zines. Send us a voice message, comment or question.   Show Links:   Antonio M. Rosario's Website, Vero, Instagram, Bluesky, and Facebook page Ward Rosin's Website, Vero, Bluesky, Instagram and Facebook page. Ornis Photo Website  The Unusual Collective Street Shots Facebook Page Street Shots Instagram     Subscribe to us on: Apple Podcasts Google Podcasts Spotify Amazon Music iHeart Radio

DJI's new Mavic 4 Pro brings true D-Log to all three cameras and a 360° rotating gimbal – but is it enough to replace your camera? Nino and Johnnie also dive into Panasonic's LUMIX S1II and S1IIE, covering ProRes RAW, a stacked sensor, and CineD's lab test results. Brought to you by CineD.com – your source for filmmaking tech news, reviews, and education. Tune in and get all the details! Sponsor: This episode is sponsored by FUJIFILM. Check it out at (28:13)   Chapters & Articles Mentioned in This Episode:   (00:00) -  Intro (01:53) - DJI Mavic 4 Pro First Look Review – D-Log 10-Bit on All Cameras, 6K Video, and a Fully Rotating Gimbal https://www.cined.com/dji-mavic-4-pro-first-look-review-d-log-10-bit-on-all-cameras-6k-video-and-a-fully-rotating-gimbal/   (29:13) - Panasonic LUMIX S1II Camera Released – Partially Stacked Sensor, 5.9K 60fps, Open Gate, Internal ProRes RAW, and More https://www.cined.com/panasonic-lumix-s1ii-camera-released-partially-stacked-sensor-5-9k-60fps-open-gate-internal-prores-raw-and-more/ Panasonic LUMIX S1II Review - First Impression and a Mini-Documentary https://www.cined.com/panasonic-lumix-s1ii-review-first-impression-and-a-mini-documentary/    (47:26) - Panasonic Future Firmware Updates for the LUMIX S1II, S1IIE and S1RII Annou nced https://www.cined.com/panasonic-future-firmware-updates-for-the-lumix-s1ii-s1iie-and-s1rii-announced/   (48:47) - Panasonic LUMIX S1IIE Camera Announced – the “Essential” Version of the S1II https://www.cined.com/panasonic-lumix-s1iie-camera-announced-the-essential-version-of-the-s1ii/   (52:09) - Panasonic LUMIX S 24-60mm f/2.8 Standard Zoom Lens for L-Mount Released – Compact and Lightweight https://www.cined.com/panasonic-lumix-s-24-60mm-f-2-8-standard-zoom-lens-for-l-mount-released-compact-and-lightweight/   (56:31) - Panasonic LUMIX S1II Lab Test – Rolling Shutter, Dynamic Range, and Exposure Latitude https://www.cined.com/panasonic-lumix-s1ii-lab-test-rolling-shutter-dynamic-range-and-exposure-latitude/ We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com   

Túl vagyunk egy nagy, két napos munkán. Elmeséljük milyen volt hajnali 2-kor felébredve végigfotózni a napot. Milyen volt egyszerre több helyen fotózni, milyenek voltak az asszisztensek, és hogyan használtuk a bérelt eszközöket.Az adás linkje:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/148Támogass minket Patreonon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Csatlakozz a Tripodcast Community Facebook csoporthoz!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://tripodcast.hu/community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adást a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fujifilm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, a ⁠⁠⁠⁠⁠⁠Manfrotto⁠⁠⁠⁠⁠⁠ és az ⁠⁠⁠Ablak Stúdió⁠⁠⁠ támogatta!Kövess minket Instán:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/tripodcast_⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adásban elhangzott témák, linkek:- Caruba összecsukható kocsi:https://www.unidomestore.hu/caruba-opvouwbare-transport-trolley-32251- Vevor összecsukható kocsi:https://eur.vevor.com/garden-cart-c_10251/vevor-collapsible-folding-wagon-400l-beach-wagon-cart-heavy-duty-225-lbs-p_010963071047- Parabolix parabola reflector:https://www.parabolixlight.com- Broncolor Para 133:https://www.bhphotovideo.com/c/product/1211918-REG/broncolor_b_33_550_03_para_133_reflector_kit.html- Photek Soflighter:https://www.bhphotovideo.com/c/product/1335445-REG/photek_sl_5000_fg_46_softlighter_umbrella_w.html- Godox ST szériás softboxok:https://www.godox.com/product-d/ST-Series.html- Peti octoboxa:https://www.mikrosat.hu/spd/740030233893/Mikrosat-8Click-Nyithato-Octobox-150cm- Peti stripboxa:https://www.mikrosat.hu/Mikrosat-4Clicks-25x100cm-Nyithato-Softbox-Mehsejt

Neale invites Kev to street photograph and adventure with him in Kolkata and Varanasi as he prepares for the next 2026 Photowalk adventure in India, but will he say yes. Also on the show a VERY special offer from our wonderful sponsor Pictime, called 72, plus an invite to come and join us on a special Pictime Zoom show on Wednesday 14th May at 6pm UK time, invite URL below. Questions into the show about lost custom settings, website picture layout nightmares, finding a discreet camera system for shooting unobtrusively, the classic Fujinon lens line-up for the X-system, protecting gear from bangs and knocks in the bag, ChatGPT accuses Neale of stealing Kev's 35mm, a 500mm beast, and battery talk.  THE BIG ZOOM INVITE for 14th March 6pm UK time: https://www.fujicast.co.uk/pictime  Email the show with your questions: click@fujicast.co.uk  Pic Time: https://www.pic-time.com/ - use FUJICAST when creating an account for discount offers to apply For links go to the showpage.

In recent years, the rise of vertical video shooting has grown significantly. We recently conducted a poll asking our community how they handle this during their productions. Do people tend to crop into horizontal videos, or are they flipping the cameras to shoot dedicated vertical shots? What needs to be considered when shooting vertical? We dive into this topic and, of course, bring you the usual gear updates in this week's episode. Tune in and get all the insights from this week's discussion! Sponsor: This episode is sponsored by FUJIFILM. Check it out at (20:58)   Chapters & Articles Mentioned in This Episode: (00:00) -  Intro   (03:50) - Poll: Are You Filming Vertically? https://www.cined.com/poll-are-you-filming-vertically/   (13:34) - Aspect Ratio Control for Everyone! https://www.cined.com/aspect-ratio-for-everyone/   (21:58) - Trump Proposes 100% Tariff on Films Produced Outside the U.S., Industry Wonders What That Actually Means https://www.cined.com/trump-proposes-100-tariff-on-films-produced-outside-the-u-s-industry-wonders-what-that-actually-means/   (31:21) - ZEISS Virtual Lens Tech for Compositing Previewed – Real Lens Behavior for Digital Content https://www.cined.com/zeiss-virtual-lens-tech-for-compositing-previewed-real-lens-behavior-for-digital-content/   (38:10) - TTArtisan 35mm T2.1 Cine Lens Introduced with Dual Bokeh – Bubble and Soft https://www.cined.com/ttartisan-35mm-t2-1-cine-lens-introduced-with-dual-bokeh-bubble-and-soft/   (42:02) - Get Me Started with Adobe Premiere Pro https://www.mzed.com/courses/get-me-started-premiere-pro   (43:55) - Canon RF 75-300mm f/4-5.6 Announced – Budget Telephoto Zoom for the RF System https://www.cined.com/canon-rf-75-300mm-f-4-5-6-announced-budget-telephoto-zoom-for-the-rf-system/ (45:44) - Blackmagic DaVinci Resolve 20 Beta 3 Released https://www.cined.com/blackmagic-davinci-resolve-20-beta-3-released/   (48:26) - Blackmagic Camera 9.5.1 & 9.5.2 Firmware Updates https://www.cined.com/blackmagic-camera-9-5-1-firmware-update-brings-improvements-to-ursa-cine-cameras/   (50:42) - CineD Best-of-Show Awards at Cine Gear 2025 – Submissions Open Now https://www.cined.com/cined-best-of-show-awards-at-cine-gear-2025-submissions-open-now/   (58:24) -B&H BILD Expo Returns to New York City in June, with CineD Talk – Free Registration Now Open https://www.bildexpo.com/?ref=AFFCineD&BI=7953&KBID=8488  https://www.cined.com/bh-bild-expo-returns-to-new-york-city-in-june-with-cined-talk-free-registration-now-open/   We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com

Episode 466 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Benro Spring savings at BenroUSA.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: This photographer shows what not to do. (#) Canon's new 75-300mm f/4-5.6 sure seems familiar. (#) Nikon looks to hit 50 in short order. (#) MAP Camera's top 20 is telling. (#) Grecco goes to the mat for photographers. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

TurdOrTreasure is ThisWeekInGeek's dedicated review show covering everything from games to movies to tv to electronics and everything between.This Episode:What's New?Kensington Device Security Study Discussion - https://www.kensington.com/en-ca/c/products/security/?srt=relevanceFUJIFILM Printlife Mother's Day Gift Ideas (Mother's Day Gift Guide) -https://fujifilmprintlife.ca/Egging On (PC Steam First Impressions Review) -https://store.steampowered.com/app/2897610/Egging_On/HITMAN World of Assassination (iOi PS5 & PSVR2 First Impressions Review) - https://ioi.dk/hitmanShark TurboBlade Ultra-Powerful Bladeless Tower Fan (Kitchen Tech Review) -https://www.sharkclean.ca/products/shark-turboblade-fan-xl-zidTF202CMay Movie Roundup (88Films And Mill Creek Bluray Reviews) -Gate Of Flesh - https://www.blu-ray.com/movies/Gate-of-Flesh-Blu-ray/383510/Lady Of The Law - https://www.blu-ray.com/movies/Lady-of-the-Law-Blu-ray/383022/Ultraman Trigger: Complete Series + Ultraman Trigger Episode Z - https://www.blu-ray.com/movies/Ultraman-Trigger-Complete-Series-and-Ultraman-Trigger-Episode-Z-Blu-ray/379198/Masters of the Universe: Revelation / Revolution Blu-ray SteelBook - https://www.blu-ray.com/movies/Masters-of-the-Universe-Revelation-and-Revolution-Blu-ray/383293/Your Geekmaster:Alex "The Producer" - https://bsky.app/profile/dethphasetwig.bsky.socialFeedback for the show?:Email: feedback@thisweekingeek.netTwitter: https://twitter.com/thisweekingeekBluesky: https://bsky.app/profile/thisweekingeek.bsky.socialYouTube: https://www.youtube.com/channel/UCc1BfUrFWqEYha8IYiluMyAiTunes: https://podcasts.apple.com/us/podcast/this-week-in-geek/id215643675Spotify: spotify:show:0BHP4gkzubuCsJBhU3oNWXCastbox: https://castbox.fm/channel/id2162049Website: https://www.thisweekingeek.netMay 5, 2025

Send us a textIn this episode of the SheClicks Women in Photography Podcast, Angela Nicholson chats with Dom Shaw, co-founder of York Place Studios, former Fujifilm ambassador (X Photographer) and documentary wedding photographer with a gift for finding magic in small, everyday moments.Dom reflects on how a childhood surrounded by photography inspired her passion for capturing real, unposed stories. From working in a darkroom in her family's attic to travelling the world shooting weddings and street photography, Dom's creative journey has been fuelled by a love of authenticity and connection.She shares the importance of staying true to your photographic voice, even when commercial pressures threaten to pull you in other directions. Angela and Dom also discuss Is This Something?, the inspirational book Dom co-wrote with her brother Liam, aimed at helping photographers capture meaningful, spontaneous images rather than posed perfection.Throughout the conversation, Dom offers heartfelt advice on trusting your instincts, photographing real relationships and keeping creativity alive throughout a busy career. Whether you are just starting out or have years of experience behind the lens, Dom's passion and wisdom will leave you feeling inspired to seek the extraordinary in the ordinary.TakeawaysSmall moments often carry the deepest emotional weight — learning to spot them is key to meaningful photography.Authenticity matters more than technical perfection; real, heartfelt images resonate the most.Developing a clear creative vision helps you stay true to yourself even under commercial pressure.Composition is a vital storytelling tool — strong framing can transform an ordinary scene into something magical.Success comes from persistence and passion, not from chasing trends or perfection.Photography is not about capturing what looks good, but about preserving what feels true.Connect with DomWebsiteFacebookInstagramBookFujifilmThis podcast is supported by Fujifilm, one of the best-known photography brands in the world. Fujifilm's award-winning X Series and GFX system cameras and lenses are suitable for all types of photographers and videographers. Each has been developed utilising the experience gained from more than 90 years in the industry, featuring unique film simulation modes that everyone knows and loves.Support the show

What does it mean to carry someone else's artistic legacy forward? Bianca Cline joins the Cinematography Salon Podcast to share a rare and deeply moving look behind the lens, stepping into the unfinished production of Rust following the tragic death of cinematographer Halyna Hutchins, ASC. Bianca discusses the moral and emotional calculus behind accepting the role, her consultations with Hutchins' family, and the quiet determination to preserve Halyna's memory. A memorial scholarship has been established in Halyna's name at the AFI Conservatory. Donate here it you wish to contribute to the scholarship fund.Bianca Cline's Instagram | WebsitePeter Pascucci's Instagram | WebsiteAva Benjamin Shorr's Instagram | WebsiteThis episode is sponsored by Fujifilm, Sandisk and TCP Insurance.

Join this week's episode of Focus Check for an exclusive glimpse at an exciting new MZed course coming soon. Plus, we've got your regular dose of weekly updates on lights, lenses, and cameras. Tune in and stay until the end—you won't want to miss it! Sponsor: This episode is sponsored by FUJIFILM. Check it out at (27:14) Chapters & Articles Mentioned in This Episode: (00:00) -  Intro (01:40) - Poll: Filmmakers, Are You Taking Care of Yourself? https://www.cined.com/poll-filmmakers-are-you-taking-care-of-yourself/ Last week's Focus Check: "Cooking video" https://www.cined.com/recipes-in-focus-fuel-for-filmmakers-cined-focus-check-ep61/ (05:32) - New MZed Course coming soon https://www.mzed.com/?tap_a=17272-420962&tap_s=2964533-bb92db    (12:11) - Yongnuo YNLUX 300RGB Review – Reliable Performance on a Budget https://www.cined.com/yongnuo-ynlux-300rgb-review-reliable-performance-on-a-budget/   (16:57) - K&F Concept KF-V99 Pro and KF-V50 Review – Budget-Friendly V-Mount Batteries https://www.cined.com/kf-concept-kf-v99-pro-and-kf-v50-review-budget-friendly-v-mount-batteries/   (28:11) - Sony a7S III Firmware Update Version 4.00 Released – Adds In-Camera LUTs and More https://www.cined.com/sony-a7s-iii-firmware-update-version-4-00-released-adds-in-camera-luts-and-more/   (38:37) - Insta360 X5 Camera Released – InstaFrame Mode, Larger Sensor, User-Replaceable Lens, and More https://www.cined.com/insta360-x5-camera-released-instaframe-mode-larger-sensor-user-replaceable-lens-and-more/   (45:46) - Sony FE 50-150mm F2 GM Unveiled – A Zoom Lens with Prime Features https://www.cined.com/sony-fe-50-150mm-f2-gm-unveiled-a-zoom-lens-with-prime-features/   (49:19) - DZOFILM Vespid Prime Lenses – Limited-Time Offer Starting at $799 https://www.cined.com/dzofilm-vespid-prime-lenses-limited-time-offer-starting-at-799/   (51:50) - Godox KNOWLED MG6K High Power LED Light Introduced https://www.cined.com/godox-knowled-mg6k-high-power-led-light-introduced/   (54:07)- DaVinci Resolve 20 Public Beta 2 Released – Speed Keyframe Improvements, Voiceover Recording Fixes, and More https://www.cined.com/davinci-resolve-20-public-beta-2-released-speed-keyframe-improvements-voiceover-recording-fixes-and-more/   (58:11) - Raw Convertor App Update – Convert ProRes RAW into CinemaDNG, Proxy, iOS Version, and More https://www.cined.com/raw-convertor-app-update-convert-prores-raw-into-cinemadng-proxy-ios-version-and-more/   We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com 

Neale's getting nervous about the footie and Kev's celebrating picture sales to clients who forgot to order ANY pictures when they got married almost a decade ago! Also on the show, trading in all the lenses you don't use for one excellent lens you will, more on the GFX IBIS-gate story and cropping in camera, being honest in reviews, wedding-centric glass, learning to shoot candidly for day-in-the-life shoots, and what is your camera doing while it's sat in your camera bag?!? The book of the week is Queer Happened Here by Marc Zinaman. Email the show with your questions: click@fujicast.co.uk  Pic Time: https://www.pic-time.com/ - use FUJICAST when creating an account for discount offers to apply For links go to the showpage.

In today's episode of Digipreneur FM, Keron dives deep into one of the biggest shifts happening in business right now: AI has become your customer's best salesperson — and many Caribbean businesses (and businesses globally) aren't ready for it. Through personal stories, real-world case studies, and practical insights, Keron reveals how today's consumers are using AI tools like ChatGPT, Perplexity, and Gemini to research, compare, and even complete purchases — all without ever speaking to a human being. You'll hear how Keron himself used AI to confidently choose a new Fujifilm camera, showcasing just how dramatically the customer journey has changed... and why businesses need to catch up — fast. If your business isn't set up to be AI-friendly, you're not just missing out — you're invisible. Tune in and learn how to future-proof your brand for the AI-driven world of commerce. 3 Key Takeaways: 1. AI is the new personal sales concierge. Customers now use AI to research products, compare competitors, find discount codes, and even finalize purchases without ever engaging a human sales rep. If you're not present online with the right digital infrastructure, you're invisible to them. 2. Businesses must be "AI-friendly" to survive. Having a fast, mobile-optimized website, e-commerce capabilities, strong SEO, and content that answers customer questions is no longer optional — it's critical if you want AI to find and recommend your business. 3. The shopping experience is now hyper-personalized and frictionless. From product discovery to checkout, AI empowers consumers to tailor every step of the buying journey to their needs. Brands that create easy paths for AI-assisted shoppers will win — everyone else will lose ground quickly. Resources Mentioned: Visit KeronRose.com to learn more about building your digital presence and taking your business global. Stay updated with the podcast at Digipreneur.FM and never miss an episode.

We welcome back Eliška to discuss the most recent Fujifilm summit and her participation in the GFX 100RF testing and so much more.  Web: https://khiria.com/ IG: https://www.instagram.com/khiria/ Email the show: FujiLoveFeedback@gmail.com Follow Marc Sadowski: ------------------------ Substack: https://substack.com/@thefilmish IG: https://www.instagram.com/marcsadowski/ YouTube: https://www.youtube.com/@film-ish

Episode 465 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Benro Spring savings at BenroUSA.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Sony's FE 50-150mm f/2 G Master. (#) Tamron's 18-300mm f/3.5-6.3 for APS-C. (#) The newest additions to Photoshop and Lightroom. (#) Profoto's new Spot Small. (#) The Viltrox AF 35mm f/1.2 LAB. (#) Flickr makes a key change to its service. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

In today's episode a photographer uses camera traps in Africa to capture elusive animals, Fujifilm teases a new camera and Nikon leverages RED. You can find the show notes here. https://liamphotographypodcast.com/episodes/episode-451-camera-traps-new-fujifilm-camera-nikonred

The X5 is the latest flagship camera from Insta360. With full 360° 8K30fps capture, enhanced low-light performance, and a 185-minute battery life, X5 is designed for all-day, all-night, all-angle shooting. Get the X5 now, the smartest and toughest 360° Camera ever made here and use code “PetaPixel” to get a free 114cm invisible selfie stick with your purchase.--This week on the PetaPixel Podcast, the team is joined by Cinematographer and Director Jessica Lee Gagné from the hit TV show Severance! She talks at length about how she approached lighting, framing, camera work, and more!--Check out PetaPixel Merch: store.petapixel.com/ We use Riverside to record The PetaPixel Podcast in our online recording studio.We hope you enjoy the podcast and we look forward to hearing what you think. If you like what you hear, please support us by subscribing, liking, commenting, and reviewing! Every week, the trio go over comments on YouTube and here on PetaPixel, but if you'd like to send a message for them to hear, you can do so through SpeakPipe.--In This Episode:00:00 - Intro07:25 - Insta360 announced the X5 360-degree camera13:02- Synology wants you to buy its official drives and restricts many features to them15:41 - Light Lens Lab is remaking the rare P. Angenieux Type S21 50mm f/1.519:48 - Fujifilm finally priced the new Instax mini 4121:31 - Fujifilm teases a "half" camera22:57 - Viltrox announced a new 35mm f/1.213:35 - Sorry, but we have to talk about tariffs again...25:48 - Blackmagic was going to build a US factory, but tariffs made it untenable26:51 - Harman is raising film prices in the US30:26 - Japan has no idea what the US wants33:21 - Fujifilm confirms it has paused shipments of some cameras amid trade disarray35:28 - Nikon's vending machine mini cameras have arrived in the US39:01 - Severance's Jessica Lee Gagné on Cinematography, Directing, and More!1:13:22 - What have you been up to?1:18:16 - Tech support1:31:38 - Feel good story of the week

Episode 464 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Great deals on Calibrite gear at Calibrite.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Nikon's new Z5 II. (#) This Canon lens can't keep it together. (#) A legend has passed. (#) ProGrade Digital's latest offerings. (#) Key updates for Nikon's Zf. (#) Panasonic finally gets onboard. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Episode 463 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - 20% OFF at BenroUSA.com with code SHARKY2025. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Fujifilm's new GFX100RF. (#) Canon on the why behind sensor decisions. (#) OM System's computational photography and limitations. (#) Nextorage does a first with these cards. (#) The future for X-Pro series cameras. (#) Magnum's monumental task. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).